Prime Capital Investment Advisors LLC Has $52.63 Million Stock Position in Eli Lilly and Company $LLY

Prime Capital Investment Advisors LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 7.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 68,978 shares of the company’s stock after buying an additional 4,774 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $52,630,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Dash Acquisitions Inc. grew its position in Eli Lilly and Company by 2.8% during the second quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after buying an additional 13 shares in the last quarter. Nvest Financial LLC raised its holdings in Eli Lilly and Company by 0.6% in the 2nd quarter. Nvest Financial LLC now owns 2,274 shares of the company’s stock valued at $1,773,000 after acquiring an additional 13 shares in the last quarter. MPS Loria Financial Planners LLC lifted its position in shares of Eli Lilly and Company by 1.9% in the 2nd quarter. MPS Loria Financial Planners LLC now owns 699 shares of the company’s stock worth $545,000 after acquiring an additional 13 shares during the period. Key Client Fiduciary Advisors LLC grew its holdings in shares of Eli Lilly and Company by 1.2% during the 3rd quarter. Key Client Fiduciary Advisors LLC now owns 1,136 shares of the company’s stock worth $867,000 after purchasing an additional 13 shares in the last quarter. Finally, Darwin Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 3.6% during the 3rd quarter. Darwin Wealth Management LLC now owns 373 shares of the company’s stock worth $285,000 after purchasing an additional 13 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 beat + bullish 2026 guidance — Lilly reported stronger‑than‑expected Q4 revenue and EPS and guided FY‑2026 revenue and EPS above consensus, a primary driver of the recent rally. Eli Lilly shares soar after Q4 beat
• Positive Sentiment: Morgan Stanley raised its price target to $1,313, signaling increased analyst confidence and additional upside in the stock. Price Target Raised to $1,313.00 at Morgan Stanley
• Positive Sentiment: JPMorgan raised its price target to $1,300 and kept an overweight rating — another endorsement that likely supported buying. Price Target Raised to $1,300.00 at JPMorgan Chase & Co.
• Positive Sentiment: Cantor Fitzgerald lifted its target to $1,205 and cited easing GLP‑1 pricing fears thanks to Lilly’s outlook, reinforcing the bullish narrative. Price Target Raised to $1,205.00 at Cantor Fitzgerald
• Positive Sentiment: Capacity investment — Lilly announced a ~$3.5B manufacturing facility in Pennsylvania to expand production, supporting the company’s ability to meet rising GLP‑1 demand. Lilly to Invest Over $3.5 Billion in New Manufacturing Facility
• Neutral Sentiment: Brokerage consensus remains constructive — brokerages give LLY a “moderate buy” consensus, which supports the longer‑term case but may limit near‑term surprise potential. Given Consensus Rating of “Moderate Buy”
• Neutral Sentiment: Minor institutional repositioning — Alecta reportedly trimmed its Lilly stake; typical portfolio rotations can add volume but are not a major directional force alone. Alecta Trims Eli Lilly Stake
• Negative Sentiment: Low‑cost competitor noise — Hims & Hers announced a $49 compounded oral GLP‑1 offering, which sparked a selloff amid concerns about pricing pressure and the durability of branded margins. That announcement caused a sharp intraday pullback. Novo and Eli fall after Hims & Hers announce $49 copy
• Negative Sentiment: Investor/legal probes — Two investor alerts (Scott+Scott and Kahn Swick) are investigating Lilly’s directors/officers and a proposed Ventyx transaction; these raise governance/transaction risk and can increase short‑term volatility. Scott+Scott Investor Alert Kahn Swick Ventyx Alert

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,020.39 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The stock has a market capitalization of $964.66 billion, a price-to-earnings ratio of 44.46, a P/E/G ratio of 0.82 and a beta of 0.39. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The firm’s 50-day moving average price is $1,052.61 and its two-hundred day moving average price is $896.17.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 112.50%. Eli Lilly and Company’s quarterly revenue was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a $1.73 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is presently 29.35%.

Wall Street Analyst Weigh In

Several research analysts recently commented on LLY shares. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Friday, December 19th. Berenberg Bank increased their price objective on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research note on Tuesday, December 2nd. Morgan Stanley lifted their target price on shares of Eli Lilly and Company from $1,290.00 to $1,313.00 and gave the company an “overweight” rating in a research report on Thursday. Scotiabank reissued an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday. Finally, HSBC restated a “hold” rating and set a $1,070.00 price target on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,201.17.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.